糖尿病管理
医学
血糖性
胰岛素
糖尿病
重症监护医学
连续血糖监测
血糖监测
1型糖尿病
远程医疗
2型糖尿病
医疗保健
内科学
内分泌学
经济增长
经济
作者
Andreas Thomas,Thomas Haak,Astrid Tombek,Bernhard Kulzer,Dominic Ehrmann,Olga Kordonouri,Jens Kröger,Oliver Schubert-Olesen,Ralf Kolassa,Thorsten Siegmund,Nicola Haller,Lutz Heinemann
标识
DOI:10.1177/19322968241267768
摘要
Today, continuous glucose monitoring (CGM) is a standard diagnostic option for patients with diabetes, at least for those with type 1 diabetes and those with type 2 diabetes on insulin therapy, according to international guidelines. The switch from spot capillary blood glucose measurement to CGM was driven by the extensive and immediate support and facilitation of diabetes management CGM offers. In patients not using insulin, the benefits of CGM are not so well studied/obvious. In such patients, factors like well-being and biofeedback are driving CGM uptake and outcome. Apps can combine CGM data with data about physical activity and meal consumption for therapy adjustments. Personalized data management and coaching is also more feasible with CGM data. The same holds true for digitalization and telemedicine intervention (“virtual diabetes clinic”). Combining CGM data with Smart Pens (“patient decision support”) helps to avoid missing insulin boluses or insulin miscalculation. Continuous glucose monitoring is a major pillar of all automated insulin delivery systems, which helps substantially to avoid acute complications and achieve more time in the glycemic target range. These options were discussed by a group of German experts to identify concrete gaps in the care structure, with a view to the necessary structural adjustments of the health care system.
科研通智能强力驱动
Strongly Powered by AbleSci AI